TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00182039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
Study: NCT02719496
Drug: IBEROGAST
Normalized name: Iberogast Softgels
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00808093
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 100 mg study drug
Study: NCT00867165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
Study: NCT03694717
Drug: Saline Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
Study: NCT01729299
Drug: acyl ghrelin
Normalized name: gellan gum (low acyl)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01479868
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
Study: NCT05441631
Drug: Subcutaneous Insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Insulin dose was titrated according to the Blood glucose level~* monitoring according to glucose in urine
Study: NCT04317040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is given on Day 1.
Study: NCT00004092
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00004092
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00617604
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally
Study: NCT05261971
Drug: Etodolac 400 MG
Normalized name: etodolac 400 MG
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.
Study: NCT01102803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill
Study: NCT00286351
Drug: Combined treatment with Arimidex and Zoladex before IVF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02534350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally or via NG tube once daily
Study: NCT02778958
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
Study: NCT00176813
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02387099
Drug: Standard Care after 24 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
Study: NCT01011673
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac 30mg IVSS
Study: NCT00700596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control or Placebo SA (30 % ethanolic solution)
Study: NCT01632020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
Study: NCT02098330
Drug: Ginkgo biloba & Methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
Study: NCT02249351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01017666
Drug: BIIB014
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
Study: NCT01017666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
Study: NCT00867230
Drug: FTS
Normalized name: tuftsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
Study: NCT03760835
Drug: Dual release hydrocortisone (plenadren)
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of congenital adrenal hyperplasia
Study: NCT01078441
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01078441
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00139230
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01847963
Drug: Sindhuvallathy mezhugu ( SVM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
Study: NCT01847963
Drug: Kalladaippu Kudineer (KK) -
Approvals — FDA: no, EMA: no, PMDA: no
Description: 130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
Study: NCT02714569
Drug: LY3202328
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02714569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02714569
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01887132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03390465
Drug: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Study: NCT01655927
Drug: Placebo: Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03427125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive Drug
Study: NCT00644020
Drug: mitomycin, Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
Study: NCT04603586
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
Study: NCT03671746
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Ketorolac at 30 mg IV every 6 hours for their first 5 days of hospitalization
Study: NCT00345761
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
Study: NCT02798835
Drug: Adductor canal catheter
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
Study: NCT02798835
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: May or may not be used in spinal anesthetic
Study: NCT01451489
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
Study: NCT00168922
Drug: Bendamustin/Ribomustin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00046995
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00046995
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03684213
Drug: Norepinephrine + Ascorbic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.
Study: NCT03684213
Drug: Norepinephrine + L-NAME
Normalized name: L-Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.
Study: NCT03684213
Drug: Norepinephrine + L-NAME + Ascorbic Acid
Normalized name: L-Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
Study: NCT00636064
Drug: Parecoxib Sodium/Valdecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Study: NCT00636064
Drug: Placebo/Valdecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Study: NCT03951207
Drug: Rosuampin 10/5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
Study: NCT03951207
Drug: Rosuampin 20/5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuampin 20/5mg qd for 8 weeks
Study: NCT03399370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study: NCT01839578
Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~* 4% trisodium citrate solution~* Calcium chloride solution (100 mmol/L)~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~* Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~* Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~* Blood flow adapted to the acid-base status
Study: NCT01839578
Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)
Normalized name: ANTICOAGULANT CPDA-1 THE CLX SYSTEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~* Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~* Standard dialysate for CRRT : Prismasol® K2 solution~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of
Study: NCT03907098
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice
Study: NCT02929485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200mg) administered at study visit
Study: NCT01755949
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
Study: NCT00539994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg BID placebo 5 days
Study: NCT00356681
Drug: AMG 706 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded placebo
Study: NCT03738111
Drug: TG02 Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG02 citrate capsules
Study: NCT02867566
Drug: IBI301 plus CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
Study: NCT00584883
Drug: ABT 510
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
Study: NCT01245452
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
Study: NCT03832816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vapor (distilled water)
Study: NCT03832816
Drug: Vaporized THC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute exposure to vaporized THC
Study: NCT03832816
Drug: Vaporized CBD alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute exposure to vaporized CBD
Study: NCT03832816
Drug: Vaporized CBD with THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute exposure to vaporized CBD with THC
Study: NCT00264199
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same rate of infusion as GLP-1
Study: NCT00239733
Drug: Anti-D
Normalized name: D-Gam Anti-D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute infusion administered in an outpatient setting
Study: NCT00415285
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00415285
Drug: Docetaxel/Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01736891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, qd
Study: NCT00841633
Drug: Induced hypertension with norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
Study: NCT00114699
Drug: CCR5mAb004
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02708095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02491723
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with bronchiectasis treated with Azithromycin for three to five days.
Study: NCT00760955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
Study: NCT03259555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally daily for 3 weeks.
Study: NCT02021669
Drug: Omega-3 supplement
Normalized name: Systane Vitamin Omega-3 Supplement Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
Study: NCT02021669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
Study: NCT04090411
Drug: Induction- PF-06480605 150 mg SC Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06480605
Study: NCT04090411
Drug: Induction- PF-06480605 450 mg SC Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06480605
Study: NCT04090411
Drug: Chronic- PF-06480605 150 mg SC Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06480605
Study: NCT04395989
Drug: D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
Study: NCT00209859
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01242592
Drug: Anti-Tuberculosis Treatment
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03213249
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
Study: NCT04395989
Drug: D2: nab-paclitaxel, with maintenance of capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
Study: NCT01112397
Drug: AZD1480
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous daily oral capsule
Study: NCT01943799
Drug: OAV Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
Study: NCT00286585
Drug: Inhalational anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane, dosage according to the physician in charge
Study: NCT04151407
Drug: Drug 601
Normalized name: ethanol 0.601 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
Study: NCT04437485
Drug: Antidepressant Medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
Study: NCT03196804
Drug: LC28-0126
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC28-0126
Study: NCT03196804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02020616
Drug: LY3053102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05487521
Drug: Methylprednisolone and or prednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: we gave methylprednisolone and or prednisolone to patients with EEG activity and follow up the effect of the drug on language
Study: NCT04026321
Drug: SQ001 125mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
Study: NCT04026321
Drug: SQ001 250mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute